Trial Profile
A Double-blind, Double-dummy, Randomised, Parallel-group Study Comparing the Efficacy, Safety and Tolerability of Pramipexole Extended Release Versus Pramipexole Immediate Release Administered Orally for 18 Weeks in Chinese Parkinson's Disease (PD) Patients Who Can be Concomitantly Treated With Levodopa
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Dec 2014
Price :
$35
*
At a glance
- Drugs Pramipexole (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 11 Jan 2012 Actual patient number (475) added as reported by ClinicalTrials.gov.
- 11 Jan 2012 Actual end date ( Jan 2012) added as reported by ClinicalTrials.gov.
- 11 Jan 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.